June 9, 2019

Varian Acquires Interventional Oncology Companies

June 10, 2019—Varian Medical Systems, Inc. announced that it has acquired the Endocare and Alicon companies to expand its portfolio of multidisciplinary integrated cancer care solutions. Endocare, based in Austin, Texas, is a provider of hardware and software solutions supporting cryoablation and microwave ablation. Alicon, which is based in Hangzhou, China, develops embolic therapy for treating liver cancer in China.

Endocare's lead product is the Cryocare CS system, a fully integrated planning, placement, and treatment system designed to simplify cryotherapy.

Alicon's lead product is Caligel, calibrated resorbable gelform particles commonly used as an embolic agent in China for treating liver cancer. Alicon has an integrated R&D, manufacturing, and commercialization infrastructure.

According to Varian, these acquisitions provide the company with a leading position in the interventional oncology segment. Varian will leverage the existing product portfolios of both companies as well as the active R&D programs in Austin and Hangzhou. These acquisitions will allow the combined organization to develop innovations in interventional oncology and provide a wider range of cancer care solutions delivered through Varian's global platform.


June 12, 2019

Age-and-Outcomes Analysis of the VQI Supports TCAR in Elderly Patients

June 6, 2019

UK MHRA Issues Recommendations on Use of Paclitaxel Devices in PAD